



ALASKA STATE LEGISLATURE

Representative Genevieve Mina

Chair, House Health and Social Services Committee

Serving House District 19: Airport Heights, Mountain View, & Russian Jack

CSHB 195 Explanation of Changes Version I to G 05.14.26

“An Act changing the term ‘physician assistant’ to ‘physician associate’; relating to physician associates; relating to collaborative practice agreements for pharmacists; relating to the prescription of overdose drugs; relating the prescription and administration of drugs and devices by pharmacists; relating to reciprocity for pharmacists; amending the definition of ‘practitioner’; and providing for an effective date.”

(title change)

Sections 1, 2, 3, 7, 8, 9, 10, 11, 12 amends the term “physician assistants” to “physician associates”

Section 13 is amended to add a statutory reference for the definition of “opioid overdose drug”

Section 14 is amended to require that the licensee prescribing opioids under certain high-risk conditions must also prescribe an opioid overdose drug to the patient

Sections 15-24 amends the term “physician assistants” to “physician associates”

Section 25 is amended to add a statutory reference for the definition of “opioid overdose drug”

Section 26 is amended to require that an advanced practice registered nurse prescribing opioids under certain high-risk conditions must also prescribe an opioid overdose drug to the patient

Section 27 is amended to require that the licensee prescribing opioids under certain high-risk conditions must also prescribe an opioid overdose drug to the patient

Section 28 amends language to align statutory references to the Federal drug schedule within the prescription drugs monitoring program (PDMP) statutes

Section 35 is amended to reinforce that pharmacists cannot prescribe controlled substances (unless they are being used for the purpose of medication assisted therapy for opioid use disorder in a clinic), prescribe or administer high-risk, specialty drugs that are listed on the FDA’s risk evaluation and mitigation strategies (REMS), or medications or devices that are on a limited distribution network and not widely available in community pharmacies

Sections 37, 40, 41, 42, 43, 44 amends the term “physician assistants” to “physician associates”

Section 45 amends the definition of “practitioner” to include only those pharmacists who hold a DEA license and are prescribing controlled substances are required to register with the controlled substance prescription database (PDMP)

Sections 46-83 amends the term “physician assistants” to “physician associates”



ALASKA STATE LEGISLATURE

Representative Genevieve Mina

Chair, House Health and Social Services Committee

Serving House District 19: Airport Heights, Mountain View, & Russian Jack

HB 195 Explanation of Changes Version A to I (34-LS0909\I) 02.25.26

"An Act relating to the prescription and administration of drugs and devices by pharmacists; relating to reciprocity for pharmacists; and providing for an effective date."

Section 1 adds a new section to AS 08.02 that prohibits the Department of Commerce, Community, and Economic Development from requiring fees for collaborative practice agreements, requiring board approval for collaborative practice agreements, or from defining the nature and scope of services provided under these agreements and requires that each collaborative practice agreement must define the specific patient care services the pharmacist is permitted to provide under that agreement.

Section 5 is amended to adjust the timeframe to complete continuing education (CE) requirements for pain management and opioid use and addiction to align with other types of CE timeframes.

Section 7 is amended to specify that a pharmacist may provide patient care services for a condition requiring a new diagnosis only if they use a test to guide their clinical decision-making and the test is waived under the Clinical Laboratory Improvement Amendments (CLIA).

Section 8 is amended to explicitly exclude the prescription or administration of Schedule IA or IIA state-controlled substances (and Schedule II federal substances) from these services, unless used for treating opioid use disorder in a clinic (medication assisted treatment).

Section 13 updates the effective date from January 1, 2026 to January 1, 2027.